Results 231 to 240 of about 468,607 (303)

In Vitro Evaluation of Aryl Hydrocarbon Receptor Involvement in Feline Coronavirus Infection. [PDF]

Viruses
Del Sorbo L, Giugliano R, Cerracchio C, Iovane V, Salvatore MM, Serra F, Amoroso MG, Pellegrini F, Levante M, Capozza P, Diakoudi G, Galdiero M, Fusco G, Pratelli A, Andolfi A, Fiorito F.   +15 more
europepmc   +1 more source

Mast Cells in Acute COVID‐19 Patients

Allergy, EarlyView.
Ilan Zaffran, Hadas Pahima, Eli Ben‐Chetrit, Amir Jarjoui, Ilaria Puxeddu, Carl Zinner, Joana Vitte, Alexandar Tzankov, Francesca Levi‐Schaffer   +8 more
wiley   +1 more source

Human brain matters: Navigating the neuropathology of COVID‐19

Brain Pathology, EarlyView.
Severe COVID‐19 is associated with vascular dysregulation and chronic neuroinflammation, leading to axonal injury and neurodegeneration. In long COVID or PASC, persistent alterations in neuroimaging and biofluid biomarkers reflect ongoing neuronal damage and neuroinflammation, contributing to long‐term neurological symptoms including fatigue, cognitive
Juliana M. Nieuwland, Angelica Scaramuzza, Marianna Bugiani, Wilma D. J. van de Berg, Jinte Middeldorp   +4 more
wiley   +1 more source

Stimulator of interferon genes (STING) inhibits coronavirus infection by disrupting viral replication organelles. [PDF]

J Med Virol
Song K, Hasan A, Hao W, Wu Y, Sun Y, Li W, Wang L, Li S.   +7 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Cellular Nanoparticles Treat Coronavirus Infection <i>in Vivo</i>. [PDF]

Nano Lett
Yu Y, Silva-Ayala D, Zhou Z, Peng Y, Fang RH, Gao W, Griffiths A, Zhang L.   +7 more
europepmc   +1 more source

Pandemic of coronavirus infection

Indian Journal of Physical Therapy and Research, 2020
openaire   +1 more source

Mutational Signature‐Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian Cancer

Cancer Science, EarlyView.
A whole‐exome sequencing–based mutational signature biomarker (MSBM) identified an HRD‐enriched population in advanced ovarian cancer. In a phase II trial, olaparib maintenance suggested clinically meaningful PFS benefit without bevacizumab, supporting MSBM as a complementary HRD assessment approach.
Katsutoshi Oda, Daisuke Shintani, Akira Nishijima, Mayuyo Mori, Kazuyoshi Kato, Shoji Nagao, Noriomi Matsumura, Masahiro Kagabu, Masataka Takenaka, Kosuke Yoshihara, Yosuke Konno, Junzo Hamanishi, Sho Sato, Shiro Takamatsu, Keiko Ueda, Kosuke Kashiwabara, Takashi Aoki, Kunihiro Nishimura, Kenji Tatsuno, Hiroyuki Aburatani, Kosei Hasegawa   +20 more
wiley   +1 more source

Mesenchymal stem/stromal cell therapy improves immune recovery in a feline model of severe coronavirus infection. [PDF]

Stem Cells Transl Med
Wanakumjorn P, Kimura K, Castillo D, McLarty E, Formaker R, Qiao R, Farrell K, Brostoff T, Ramarapu R, Pires J, Cohen-Davidyan T, Cassano J, Murphy B, Reagan K, Kol A.   +14 more
europepmc   +1 more source

Equine coronavirus infection and replication in equine intestinal enteroids. [PDF]

Vet Res
Kambayashi Y, Nemoto M, Ochi A, Kishi D, Ueno T, Tsujimura K, Bannai H, Kawanishi N, Ohta M, Suzuki T.   +9 more
europepmc   +1 more source